Nonprofit · EIN 95-4296919
INTERNATIONAL MYELOMA FOUNDATION
Tax-exempt · STUDIO CITY, CA 91604
Financials
| Year ended | Form | Revenue | Expenses | Net income | Total assets | Liabilities | Net assets |
|---|---|---|---|---|---|---|---|
| September 30, 2025 | 990 | $18,271,874 | $18,451,838 | -$179,964 | $18,291,125 | $7,536,538 | $10,754,587 |
| September 30, 2024 | 990 | $18,983,815 | $20,796,076 | -$1,812,261 | $16,882,003 | $6,629,903 | $10,252,100 |
| September 30, 2023 | 990 | $16,745,686 | $18,411,117 | -$1,665,431 | $18,245,423 | $7,727,579 | $10,517,844 |
Financial details: 990 for the year ended September 30, 2025
Revenue
- Contributions, gifts and grants
- $17,926,016
- Program service revenue
- $15,655
- Investment income
- $330,203
- Other revenue
- $0
Expenses
- Grants and similar amounts paid
- $212,000
- Compensation of officers, directors and key employees
- $1,916,363
- Other salaries and wages
- $5,112,973
- Salaries, compensation and benefits (total)
- $7,029,336
- Professional fundraising fees
- $0
- Legal fees
- $229,800
- Accounting fees
- $66,779
- Occupancy
- $227,627
- Travel
- $947,903
- Depreciation
- $241,238
- Program services (functional)
- $15,762,547
- Management and general (functional)
- $1,239,933
- Fundraising (functional)
- $1,449,358
Balance sheet and other
- Total assets, start of year
- $16,882,003
- Total assets, end of year
- $18,291,125
- Total liabilities, end of year
- $7,536,538
- Net assets, end of year
- $10,754,587
- Land, buildings and equipment
- $849,145
- Publicly traded securities
- $11,105,971
- Net assets without donor restrictions
- $10,001,258
- Net assets with donor restrictions
- $753,329
- Gross receipts
- $18,778,439
- Employees
- 57
- Volunteers
- 317
- Year formed
- 1990
- State of legal domicile
- CA
From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.
Officers, directors and key employees
As listed on the 990 for the year ended September 30, 2025, highest compensation first.
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| DR BRIAN DURIE | CHIEF SCIENTIFIC OFFICER THRU 7/8/24 Highest-paid employee | 40 | $845,219 | $16,085 |
| JOSEPH MIKHAEL | CHIEF MEDICAL OFFICER THRU 3/31/26 Highest-paid employee | 40 | $451,416 | $21,819 |
| YELAK BIRU | CEO, PRESIDENT THRU 2/28/25 Trustee or director, Officer | 40 | $430,000 | $23,307 |
| DIANE MORAN | INTERIM CEO, SENIOR VICE PRESIDENT Officer | 40 | $427,784 | $16,916 |
| JENNIFER SCARNE | CHIEF FINANCIAL OFFICER THRU 3/13/26 Officer | 40 | $303,088 | $25,436 |
| LISA PAIK | EXECUTIVE VICE PRESIDENT Key employee | 40 | $272,519 | $30,207 |
| PETER ANTON | VICE PRESIDENT, MARKETING Key employee | 40 | $247,200 | $35,430 |
| SUSAN DURIE | FORMER - DIRECTOR OF GLOBAL PATIENT Former | 0 | $267,800 | $0 |
| ANNABEL REARDON | CHEIF OF STAFF THRU 6/14/24 Highest-paid employee | 40 | $213,152 | $5,957 |
| ROBIN TUOHY | VICE PRESIDENT, PATIENT SUPPORT Key employee | 40 | $188,384 | $30,283 |
| SYLVIA DSOUZA | VICE PRESIDENT, DEV. THRU 9/4/25 Highest-paid employee | 40 | $202,850 | $8,532 |
| KELLY R COX | SENIOR DIRECTOR THRU 4/15/24 Highest-paid employee | 40 | $187,968 | $5,004 |
| DR VINCENT RAJKUMAR | DIRECTOR, CHAIRMAN Trustee or director | 1 | $0 | $0 |
| SAGAR LONIAL | DIRECTOR, VICE-CHAIR Trustee or director | 1 | $0 | $0 |
| SANJAY SINGH | DIRECTOR, TREASURER Trustee or director | 1 | $0 | $0 |
14 more people on this return
| Name | Title | Hours / week | Compensation |
|---|---|---|---|
| ANDREW KUZNESKI III | DIRECTOR, SECRETARY Trustee or director | 1 | $0 |
| CHRISTINE BATTISTINI | DIRECTOR Trustee or director | 1 | $0 |
| LORAINE BOYLE | DIRECTOR Trustee or director | 1 | $0 |
| MARTINE ELIAS | DIRECTOR Trustee or director | 1 | $0 |
| GEORGE T HAYUM | DIRECTOR Trustee or director | 1 | $0 |
| JASON KATZ | DIRECTOR Trustee or director | 1 | $0 |
| CHARLES NEWMAN | DIRECTOR Trustee or director | 1 | $0 |
| MATTHEW ROBINSON | DIRECTOR Trustee or director | 1 | $0 |
| POORNIMA PARAMESWARAN | DIRECTOR Trustee or director | 1 | $0 |
| NIKHIL MUNSHI | DIRECTOR Trustee or director | 1 | $0 |
| KENT OLIVER | DIRECTOR Trustee or director | 1 | $0 |
| MARIA WHITMAN | DIRECTOR Trustee or director | 1 | $0 |
| JOHN O'DWYER | DIRECTOR THRU 4/30/25 Trustee or director | 1 | $0 |
| BENSON KLEIN | DIRECTOR THRU 7/31/25 Trustee or director | 1 | $0 |
990 for the year ended September 30, 2024: 24 people
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| JOSEPH MIKHAEL | CHIEF MEDICAL OFFICER Highest-paid employee | 40 | $459,562 | $18,845 |
| YELAK BIRU | CEO, PRESIDENT, DIRECTOR Trustee or director, Officer | 40 | $430,000 | $20,698 |
| DIANE MORAN | SENIOR VICE PRESIDENT - BUSINESS RELATIONSHIP MANA Highest-paid employee | 40 | $432,784 | $15,830 |
| DR BRIAN DURIE | CHIEF SCIENTIFIC OFFICER-FORMER DIR Highest-paid employee | 40 | $430,000 | $3,096 |
| SUSAN DURIE | DIRECTOR OF GLOBAL PATIENT EMPOWERMENT-FORMER DIR Highest-paid employee | 40 | $362,646 | $27,940 |
| JENNIFER SCARNE | CHIEF FINANCIAL OFFICER Officer | 40 | $303,088 | $22,273 |
| LISA PAIK | EXECUTIVE VICE PRESIDENT - RESEARCH & OPERATIONS Highest-paid employee | 40 | $275,225 | $26,338 |
| PETER ANTON | VICE PRESIDENT, MARKETING Key employee | 40 | $225,894 | $31,563 |
| ROBIN TUOHY | VICE PRESIDENT, PATIENT SUPPORT Key employee | 40 | $179,562 | $32,574 |
| CHRISTINE BATTISTINI | DIRECTOR Trustee or director | 1 | $0 | $0 |
| LORAINE BOYLE | DIRECTOR Trustee or director | 1 | $0 | $0 |
| MARTINE ELIAS | DIRECTOR Trustee or director | 1 | $0 | $0 |
| GEORGE T HAYUM | DIRECTOR Trustee or director | 1 | $0 | $0 |
| JASON KATZ | DIRECTOR Trustee or director | 1 | $0 | $0 |
| BENSON KLEIN | DIRECTOR Trustee or director | 1 | $0 | $0 |
| ANDREW KUZNESKI III | DIRECTOR Trustee or director | 1 | $0 | $0 |
| DR HEINZ LUDWIG | DIRECTOR Trustee or director | 1 | $0 | $0 |
| CHARLES NEWMAN | DIRECTOR Trustee or director | 1 | $0 | $0 |
| MATTHEW ROBINSON | DIRECTOR Trustee or director | 1 | $0 | $0 |
| DR VINCENT RAJKUMAR | CHAIRMAN Trustee or director | 40 | $0 | $0 |
| E MICHAEL SCOTT | DIRECTOR Trustee or director | 1 | $0 | $0 |
| SANJAY SINGH | DIRECTOR Trustee or director | 1 | $0 | $0 |
| JOHN O'DWYER | DIRECTOR Trustee or director | 1 | $0 | $0 |
| POORNIMA PARAMESWARAN | DIRECTOR Trustee or director | 1 | $0 | $0 |
990 for the year ended September 30, 2023: 26 people
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| JOSEPH MIKHAEL | CHIEF MEDICAL OFFICER Highest-paid employee | 40 | $455,869 | $16,868 |
| YELAK BIRU | CEO, PRESIDENT Trustee or director, Officer | 40 | $412,083 | $17,822 |
| DIANE MORAN | STRATEGIC PLANNER Highest-paid employee | 40 | $409,891 | $15,369 |
| DR BRIAN DURIE | DIRECTOR Trustee or director | 1 | $342,333 | $358 |
| JENNIFER SCARNE | CHIEF FINANCIAL OFFICER Officer | 40 | $281,385 | $20,241 |
| SUSAN DURIE | DIRECTOR Trustee or director | 40 | $256,967 | $28,716 |
| LISA PAIK | SENIOR VICE PRESIDENT Highest-paid employee | 40 | $257,083 | $23,854 |
| PETER ANTON | VICE PRESIDNENT, MARKETING Highest-paid employee | 40 | $204,913 | $28,760 |
| LYNN GREEN | SENIOR VICE PRESIDENT, PHI Highest-paid employee | 40 | $228,343 | $570 |
| JACK AIELLO | DIRECTOR Trustee or director | 1 | $0 | $0 |
| CHRISTINE BATTISTINI | DIRECTOR Trustee or director | 1 | $0 | $0 |
| DR MARIO BOCCADORO | DIRECTOR Trustee or director | 1 | $0 | $0 |
| LORAINE BOYLE | DIRECTOR Trustee or director | 1 | $0 | $0 |
| MARTINE ELIAS | DIRECTOR Trustee or director | 1 | $0 | $0 |
| GEORGE T HAYUM | DIRECTOR Trustee or director | 1 | $0 | $0 |
| JASON KATZ | DIRECTOR Trustee or director | 1 | $0 | $0 |
| BENSON KLEIN | DIRECTOR Trustee or director | 1 | $0 | $0 |
| ANDREW KUZNESKI III | DIRECTOR Trustee or director | 1 | $0 | $0 |
| DR ROBERT A KYLE | DIRECTOR Trustee or director | 1 | $0 | $0 |
| DR HEINZ LUDWIG | DIRECTOR Trustee or director | 1 | $0 | $0 |
| DR EDITH MITCHELL | DIRECTOR Trustee or director | 1 | $0 | $0 |
| CHARLES NEWMAN | DIRECTOR Trustee or director | 1 | $0 | $0 |
| MATTHEW ROBINSON | DIRECTOR Trustee or director | 1 | $0 | $0 |
| DR VINCENT RAJKUMAR | DIRECTOR Trustee or director | 1 | $0 | $0 |
| E MICHAEL D SCOTT | DIRECTOR Trustee or director | 1 | $0 | $0 |
| SANJAY SINGH | DIRECTOR Trustee or director | 1 | $0 | $0 |
Address and contacts
- Address (IRS master file)
- 4400 COLDWATER CANYON AVE STE 300, STUDIO CITY, CA 91604-5053
- In care of
- % SUSAN NOVIS
- Principal officer (990 for 2024)
- HEATHER COOPER ORTNER, 4400 COLDWATER CANYON AVE SUITE 300, STUDIO CITY, CA 91604
- Signed the 990
- HEATHER COOPER ORTNER, PRESIDENT & CEO
- Phone
- (818) 487-7455
- Website
- WWW.MYELOMA.ORG
- Return prepared by
- GURSEY SCHNEIDER LLP
California records
California keeps its own records of charities and corporations. Search them by EIN 95-4296919 or by the name INTERNATIONAL MYELOMA FOUNDATION.
- Attorney General, Registry of Charities and Fundraisers
- Registration status and filed reports (CT-TR-1, RRF-1)
- Secretary of State, bizfile Online
- Corporation status, entity number, agent for service
- Franchise Tax Board
- Entity status letter (state tax exemption, good standing)
Mission
DEDICATED TO IMPROVING THE QUALITY OF LIFE OF MYELOMA PATIENTS WHILE WORKING TOWARD PREVENTION AND A CURE.
Program accomplishments
- RESEARCH - THE INTERNATIONAL MYELOMA FOUNDATION (IMF) IS THE LEADER IN GLOBALLY COLLABORATIVE MYELOMA RESEARCH. IMF BRINGS TOGETHER THE WORLD'S LEADING EXPERTS TO COLLABORATE ON TRANSLATIONAL RESEARCH THROUGH THE INTERNATIONAL MYELOMA WORKING GROUP (IMWG), WHICH PUBLISHES TREATMENT GUIDELINES IN PRESTIGIOUS MEDICAL JOURNALS, ADVANCES RESEARCH TOWARD PREVENTION AND CURE, MENTORS THE NEXT GENERATION OF INNOVATIVE INVESTIGATORS, AND IMPROVES LIVES THROUGH BETTER CARE. IMWG IS CONSIDERED THE MOST PRESTIGIOUS ORGANIZATION FOR MYELOMA RESEARCHERS GLOBALLY. THE BLACK SWAN RESEARCH INITIATIVE IS A MULTINATIONAL CONSORTIUM OF LEADING MYELOMA EXPERTS WHO ARE HARNESSING NEW TECHNOLOGIES AND THE LATEST MYELOMA TREATMENTS TO FIND A PATHWAY TO A CURE. THE BLACK SWAN RESEARCH STRATEGY CAPITALIZES ON THE AVAILABILITY OF POTENT NOVEL THERAPIES AND THE ADVENT OF ULTRA-SENSITIVE TESTS TO MEASURE EXACTLY WHEN AND HOW THOSE THERAPIES ARE WORKING IN PATIENTS. THE BLACK SWAN RESEARCH INITIATIVE IS DEDICATED TO DEVELOPING NEW CURATIVE AND PREVENTATIVE THERAPIES FOR MYELOMA.Expenses $5,749,338 · grants $180,000
- EDUCATION AND AWARENESS - ALTHOUGH IT IS THE SECOND MOST COMMON BLOOD CANCER, MULTIPLE MYELOMA IS STILL A RELATIVELY UNKNOWN DISEASE. FOR MANY PATIENTS AND THEIR CAREGIVERS, IT IS AT DIAGNOSIS WHEN THEY FIRST HEARD THE WORD "MYELOMA". IMF RECOGNIZES THE NEED FOR COMPREHENSIVE EDUCATION PROGRAMS FOR BOTH THE PATIENT AND THE PHYSICIAN TO ENSURE THAT PATIENTS ARE DIAGNOSED CORRECTLY AND TREATED EFFECTIVELY.OUR LIBRARY OF MORE THAN 100 PUBLICATIONS FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS, IS AVAILABLE FREE OF CHARGE. PUBLICATIONS ARE UPDATED ANNUALLY AND AVAILABLE IN MORE THAN 19 LANGUAGES.THE IMF EMPOWERS PATIENTS AND THEIR CAREGIVERS TO PARTICIPATE AS ACTIVE DECISION-MAKING PARTNERS WITH HEALTHCARE PROVIDERS, LEADING TO THE BEST POSSIBLE QUALITY OF LIFE. THE IMF PRODUCES COMPREHENSIVE BUT USER-FRIENDLY INFORMATION FOR THE ENTIRE MYELOMA COMMUNITY. THE IMF'S PUBLICATIONS LIBRARY INCLUDES AN EXTENSIVE CATALOG OF BOOKLETS, TIP CARDS, ARTICLES, WEBINARS AND TELECONFERENCES, BLOGS, DIGITAL MEDIA AND INTERVIEWS, ALL WRITTEN, CREATED, AND PRODUCED BY THE IMF WITH OVERSIGHT BY ITS SCIENTIFIC ADVISORY COMMITTEE. THE IMF LIBRARY'S BROAD SCOPE INCLUDES INFORMATION ABOUT MYELOMA TREATMENT OPTIONS, CLINICAL TRIALS, DIVERSITY, EQUITY AND QUALITY OF LIFE CONSIDERATIONS FOR PATIENTS AND PHYSICIANS.Expenses $3,054,437
- PATIENT AND FAMILY SEMINARS: THE IMF'S PATIENT AND FAMILY SEMINARS PRESENT VITAL INFORMATION ABOUT NEW TREATMENTS AND CLINICAL TRIALS, PROVIDE TIME WITH MYELOMA SPECIALISTS IN INTIMATE SETTINGS, AND ALLOW PARTICIPANTS TO SHARE THEIR PERSONAL EXPERIENCES AND SUPPORT. PREMIER MYELOMA EXPERTS VOLUNTEER THEIR TIME TO EMPOWER PATIENTS AND THEIR FAMILIES TO MAKE EDUCATED TREATMENT CHOICES TAILORED TO THEIR NEEDS. IN ADDITION TO PATIENT AND FAMILY SEMINARS, THE IMF FACILITATES REGIONAL COMMUNITY WORKSHOPS, WHICH SERVE AS CONDENSED SEMINARS IN SMALLER CITIES TO EXPAND THE REACH OF IMF PROGRAMS AND UP-TO-DATE INFORMATION ON MYELOMA CARE, SUPPORT AND TREATMENT TO A WIDER AUDIENCE AT NO CHARGE.Expenses $1,867,515
- INTERNATIONAL - THE IMF GROWS ITS NETWORK OF HEALTH CARE PROFESSIONALS AROUND THE WORLD. KEY TEAM MEMBERS ORGANIZE PHYSICIAN AS WELL AS PATIENT MEETINGS IN ORDER TO PROVIDE EDUCATION ABOUT THE LATEST DEVELOPMENTS IN THE FIELD OF MULTIPLE MYELOMA.SUPPORT GROUPS - THROUGH A GLOBAL COMMUNITY OF VOLUNTEER-LED SUPPORT GROUPS, THE IMF ENSURES THAT PATIENTS AND FAMILIES HAVE LOCAL ACCESS TO SUPPORT AND EDUCATION. THE IMF CURRENTLY SUPPORTS OVER 160 SUPPORT GROUPS WORLDWIDE. THE IMF PROVIDES WEBSITE CREATION AND HOSTING FOR LOCAL SUPPORT GROUPS, AND PROVIDES A UNIQUE OPPORTUNITY FOR SUPPORT GROUP LEADERS TO ATTEND THE AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING. THE IMF HOSTS AN ANNUAL SUPPORT GROUP LEADERS SUMMIT TO PROVIDE TRAINING AND SHARING OF BEST PRACTICES FOR VOLUNTEER LEADERS. NURSE EDUCATION - THE IMF NURSE LEADERSHIP BOARD (NLB) IS A PROFESSIONAL PARTNERSHIP REPRESENTING NURSE EXPERTS CARING FOR MYELOMA PATIENTS AT LEADING MEDICAL CENTERS. FOUNDED IN NOVEMBER 2006, THE NLB BOLSTERS NURSING EDUCATION, CLINICAL CARE EXPERIENCE EXCHANGE, AND PATIENT KNOWLEDGE AND EMPOWERMENT IN AN EFFORT TO OPTIMIZE OUTCOMES FOR PATIENTS WITH MYELOMA. THE NLB HAS IMPROVED THE NURSING CARE AND SELF-CARE OF MYELOMA PATIENTS SINCE ITS INCEPTION.CLINICAL MEETINGS - IMF PLANS AND HOSTS THE WORLD'S LEADING MYELOMA EXPERTS AT ANNUAL CLINICAL MEETINGS AROUND THE GLOBE TO SUPPORT COLLABORATIVE MYELOMA-RELATED RESEARCH PROJECTS, SHARE DATA, AND AVOID DUPLICATION OF EFFORTS AND DILUTION OF VALUABLE RESOURCES. REGIONAL COALITIONS PROMOTE EXCELLENCE IN CLINICAL PRACTICE, RESEARCH AND EDUCATION AND PROVIDE CME-ACCREDITED MEDICAL EDUCATION PROGRAMS. ADVOCACY - THE IMF IS DEDICATED TO CREATING A GLOBAL COMMUNITY THAT SUPPORTS THE NEEDS OF ALL PEOPLE AFFECTED BY MYELOMA. THE IMF ADVOCATES ON BEHALF OF THOSE AFFECTED BY MULTIPLE MYELOMA TO IMPROVE ACCESS TO HIGH-QUALITY DIAGNOSTICS AND TREATMENTS, FOR FUNDING OF MYELOMA-RELATED RESEARCH, AND FOR AN END TO INSURANCE COVERAGE DISPARITIES FOR TREATMENT. THE IMF CONTINUES TO EXPAND ITS COMMITMENT TO EMPOWERING PATIENTS, FAMILIES, AND FRIENDS TO ADVOCATE ON BEHALF OF PATIENT RIGHTS.INFOLINE - THE IMF'S TOLL-FREE INFORMATION TELEPHONE LINE PROVIDES MYELOMA TREATMENT AND MANAGEMENT SUPPORT FROM COMPASSIONATE, HIGHLY TRAINED SPECIALISTS. AS NEW TREATMENT OPTIONS BECOME AVAILABLE TO TREAT MULTIPLE MYELOMA, INFOLINE COORDINATORS ANSWER QUESTIONS ABOUT MYELOMA, ITS TREATMENT, DRUG SIDE EFFECTS, OPTIONS FOR POSSIBLE CLINICAL TRIALS, OTHER HEALTH CONCERNS, AND WHERE TO FIND LOCAL SUPPORT.WEBSITE - THE IMF WEBSITE IS THE LEADING RESOURCE FOR MYELOMA-RELATED CONTENT AND THE MOST COMPLETE SOURCE OF ANSWERS FOR NEWLY DIAGNOSED PATIENTS TO THOSE LIVING WITH MYELOMA FOR MANY YEARS. THE WEBSITE PROVIDES DEEP INFORMATION FOR PATIENTS, CAREGIVERS, FAMILY MEMBERS, AND HEALTHCARE PROFESSIONALS. INFORMATION IS AVAILABLE IN MULTIPLE LANGUAGES. CONTENT FOCUSES ON THE IMF'S RESEARCH, EDUCATION, SUPPORT AND ADVOCACY INITIATIVES. IMF OFFERS THE FIRST AND ONLY GENERATIVE AI MYELOMA-SPECIFIC CHATBOT DESIGNED TO PROVIDE GENERAL INFORMATION AND SUPPORT RELATED TO MULTIPLE MYELOMA. IT IS NOT INTENDED TO REPLACE PROFESSIONAL MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT FROM QUALIFIED HEALTHCARE PROVIDERS. SEE IMF WEBSITE FOR FURTHER INFORMATION.MYELOMA TODAY - MYELOMA TODAY IS A QUARTERLY EDUCATIONAL NEWSLETTER AND THE GO-TO RESOURCE FOR THE MYELOMA COMMUNITY TO LEARN ABOUT THE LATEST ADVANCES IN MYELOMA TREATMENT, RESEARCH AND QUALITY OF LIFE ISSUES. IT IS PROVIDED FREE OF CHARGE.INFORMATIONAL MAILINGS - THE INFOPACK IS MADE UP OF A SELECTION OF THE IMF'S PUBLICATIONS AND IS DESIGNED TO PROVIDE NEWLY DIAGNOSED PATIENTS AND THEIR FAMILIES WITH A COMPLETE UNDERSTANDING OF THE DISEASE AND CARE. THE INFO PACK CONTAINS INFORMATIVE MATERIALS FREE OF CHARGE IN 19 LANGUAGES.Expenses $5,091,257 · grants $32,000 · revenue $15,655
What it must file and when
IRS records say it files Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N. Its accounting year ends in September, so each return is due on the 15th day of the 5th month after that.
| Tax year | Year ended | Due | IRS public records |
|---|---|---|---|
| 2025 | September 30, 2026 | February 16, 2027 | Not due yet |
| 2024 | September 30, 2025 | February 17, 2026 | 990 on file |
| 2023 | September 30, 2024 | February 18, 2025 | 990 on file |
IRS record
- EIN
- 95-4296919
- Tax-exempt status
- 501(c)(3): Charitable, religious, educational or scientific organization
- Foundation status
- Publicly supported organization (170(b)(1)(A)(vi))
- Donations deductible (Pub 78)
- Public charity, 50% deduction limit
- Exempt since
- 1995
- Accounting year ends
- September
- Files
- Form 990 or 990-EZ
- Category (NTEE)
- Unknown (Z99Z)
- Assets (IRS master file)
- $18,291,125
- Income (IRS master file)
- $18,778,439
Filing history
| Form | Year ended | Revenue | Expenses | Assets | Return |
|---|---|---|---|---|---|
| 990 | September 2025 | $18,271,874 | $18,451,838 | $18,291,125 | IRS |
| 990 | September 2024 | $18,983,815 | $20,796,076 | $16,882,003 | XML |
| 990 | September 2023 | $16,745,686 | $18,411,117 | $18,245,423 | XML |
| 990 | September 2022 | $18,062,675 | $16,819,032 | $18,463,467 | IRS |
| 990 | September 2021 | – | – | – | IRS |
| 990 | September 2020 | – | – | – | IRS |
| 990 | September 2019 | – | – | – | IRS |
| 990 | September 2018 | – | – | – | IRS |
990-N: the IRS bulk file holds only the latest e-Postcard per organization; earlier years come from archived copies of that file since 2020 and can have gaps (the IRS e-Postcard search lists every one). 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS (search EIN 95-4296919).
Questions about INTERNATIONAL MYELOMA FOUNDATION
- What is the EIN of INTERNATIONAL MYELOMA FOUNDATION?
- The employer identification number (EIN) of INTERNATIONAL MYELOMA FOUNDATION is 95-4296919.
- Is INTERNATIONAL MYELOMA FOUNDATION tax-exempt?
- Yes. The IRS lists it as tax-exempt under section 501(c)(3) since 1995.
- Are donations to INTERNATIONAL MYELOMA FOUNDATION tax-deductible?
- Yes. It is listed in IRS Publication 78 (Public charity, 50% deduction limit).
- Which annual return does INTERNATIONAL MYELOMA FOUNDATION file?
- Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N.
- When is the next return of INTERNATIONAL MYELOMA FOUNDATION due?
- The return for tax year 2025 (the year ending September 30, 2026) is due February 16, 2027. Form 8868 extends it by six months; the 990-N cannot be extended.
- When did INTERNATIONAL MYELOMA FOUNDATION last file with the IRS?
- The latest return in the IRS public files is the 990 for the year ended September 2025.
- Who is the principal officer of INTERNATIONAL MYELOMA FOUNDATION?
- The 990 for the year ended September 30, 2025 names HEATHER COOPER ORTNER.
- Who are the officers and directors of INTERNATIONAL MYELOMA FOUNDATION?
- The 990 for the year ended September 30, 2025 lists 29 people; 12 received compensation from the organization, the highest $845,219 (DR BRIAN DURIE, CHIEF SCIENTIFIC OFFICER THRU 7/8/24).
- How much revenue does INTERNATIONAL MYELOMA FOUNDATION have?
- On its 990 for the year ended September 30, 2025 it reported revenue of $18,271,874, expenses of $18,451,838 and total assets of $18,291,125 at year end.
Other nonprofits in STUDIO CITY
- FRIENDS OF THE IHP EIN 95-4390665 · last filed 990-EZ for 2026
- RISING TIDE EDUCATORS EIN 99-1434992 · last filed 990-EZ for 2025
- RICE GIRL PRODUCTIONS EIN 99-0285719 · last filed 990-N for 2025
- MOTION PICTURE H&W FUND EIN 95-6042583 · last filed 990 for 2024
- HARVARD-WESTLAKE SCHOOL EIN 95-1644019 · last filed 990 for 2025
- SOUTHERN CALIFORNIA GOLF ASSOCIATION EIN 95-1240720 · last filed 990 for 2024
- FILM L A INC EIN 95-4531774 · last filed 990 for 2025
- BRIDGES ACADEMY EIN 95-4659439 · last filed 990 for 2025